Study of the Safety and Usefulness of Liposomal Curcumin in Multiple Myeloma

The purpose of this study is to test the safety of in investigational drug called Liposomal curcumin (LipoCurc) and to find the highest dose that can be given without causing very severe side effects. To do this participants are given LipoCurc and are watched very closely to see what side effects they have and to make sure the side effects are not severe. If the side effects are not severe, then new participants will be given a higher dose of LipoCurc. Participants joining this study later on will get higher doses of LipoCurc than participants who join earlier. This will continue until a dose is found that causes severe but temporary side effects. Doses higher than that will not be given.

NCT Number	NCT07456605
Lead Sponsor	University Health Network, Toronto
Conditions	Multiple Myeloma Refractory, Multiple Myeloma in Relapse
Enrollment	20 participants
Start Date	2026-02-27
Primary Completion	2028-03-02 (estimated)
Study Completion	2028-03-02 (estimated)
Updated on ClinicalTrials.gov	2026-06-12